#Sweden #Stockholm #dermatology #Nevisense #SciBase

SciBase Holds Extraordinary General Meeting to Authorize Share Issuance

On December 5, 2025, SciBase Holding AB (publ), a leading global medical technology firm, convened an extraordinary general meeting in Stockholm to discuss key strategic initiatives. The meeting focused on a proposal that was shared in advance with shareholders. Following the deliberations, the board director’s proposal regarding the authorization for issuing new shares was unanimously accepted.

This authorized resolution allows the board to issue shares on multiple occasions until the next annual general meeting, specifically with deviation from existing shareholders' preferential rights. This approach aims to enable flexibility in funding and corporate maneuvers, such as facilitating payments through the issuance of shares for buying back certain warrants, specifically the series TO2. This strategic move reflects SciBase's ongoing commitment to optimizing its capital structure while safeguarding the interests of its shareholders.

SciBase’s leadership emphasized that the decision to deviate from the usual preferential rights is primarily to ensure that the company can utilize its own shares effectively in the context of buyback transactions. Understanding the importance of swift actions in dynamic market conditions, this resolution plays a crucial role in maintaining company agility and readiness for future opportunities.

Pia Renaudin, the CEO of SciBase, highlighted the long-term vision behind this decision, stating, “Empowering our board to act upon share issuance uniquely positions SciBase as we continue to lead in dermatological advancements.” This perspective aligns with ongoing efforts at SciBase to enhance its product offerings and market presence, particularly with its flagship product, Nevisense.

Nevisense is an innovative point-of-care platform that integrates artificial intelligence (AI) and advanced electrical impedance spectroscopy (EIS) technology, providing dermatologists with tools for more accurate skin cancer detection and enhanced patient care. The company’s ground-breaking approach is rooted in over two decades of research at the esteemed Karolinska Institute in Sweden, showcasing its commitment to advancing healthcare technology.

Furthermore, this initiative is anticipated to reduce overall healthcare costs while allowing clinicians to elevate patient outcomes through timely interventions. The overall mission of SciBase is centered around minimizing patient suffering and optimizing skin health management.

Since its debut on the Nasdaq First North Growth Market on June 2, 2015, SciBase has been on a trajectory of growth and innovation within the medical technology sector. As the global demand for advanced dermatological solutions continues to rise, the company aims to solidify its leadership position, leveraging new funding mechanisms to enhance product development and expansion initiatives.

The company outlined that further details regarding this meeting and strategic plans can be accessed on its official website (www.scibase.com), ensuring transparency and open communication with stakeholders and the public.

In conclusion, the extraordinary general meeting conducted by SciBase not only addresses immediate operational requirements but also paves the way for future advancements in their dermatological technology sector. With leadership making essential moves to authorize share issuances, the company looks poised to capitalize on emerging trends while continuing to prioritize patient health and safety in all their endeavors.

For more details on SciBase’s latest developments, the public is encouraged to visit their investor relations page to view press releases and financial data, showcasing the company's unwavering progress and innovation in the ever-evolving medical technology landscape.